

Meningococcal Vaccine Market Size, Share & Trends Analysis Report By Vaccine Serotype (MenACWY, MenB and MenBC, MenC, MenA, MenAC), By Vaccine Type (Conjugate, Polysaccharide, Subcapsular), By End-User (Pediatric, Adult, Travelers) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-04-24 | 0 pages | Straits Research

AVAILABLE LICENSES:

- Single User License \$4500.00
- Global Site License \$5500.00

Report description:

Meningococcal Vaccine Market Analysis and Insights

The Meningococcal Vaccine Market size is anticipated to reach USD 2.76 Billion in 2022 and it is projected to reach USD 6.14 Billion by 2031, growing at a CAGR of % during the forecast period.

The Global Meningococcal Vaccine Market Analysis report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include types, applications, and competitor analysis.

The Global Meningococcal Vaccine Market growth, Size report provides a comprehensive analysis of the Pharmaceuticals industry, analyzes and identifies changes in market conditions set to impact future business decisions by analyzing.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Meningococcal Vaccine Market includes major supplies & Independent Consultants among others.

Global Market Scope and Meningococcal Vaccine Market

The scope of the report is to provide a 360-degree view of the market outlook by assessing the entire value chain and analyzing the key Meningococcal Vaccine Market trends from 2024 to 2032 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Meningococcal Vaccine Market Country Level Analysis

The Global Meningococcal Vaccine Market Industry Analysis Research Report provides a basic overview of industry dominating market share expected 2024 to 2032. A detailed section on Meningococcal Vaccine Market share and status of critical industries is included in the report, covering. Market Segment by Regions (North America, Europe, Asia Pacific, South America and The Middle East and Africa), coverage with region wise data from 2024 to 2032.

Top Players in Meningococcal Vaccine Market

Some of the other major highlights of the demand for Meningococcal Vaccine Market include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter's Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Meningococcal Vaccine Market during the forecast period.

GlaxoSmithKline Plc.

Sanofi S.A.

Pfizer Inc.

Serum Institute of India Pvt. Ltd

Bio-Manguinhos

Bio-Med Pvt. Limited

Chongqing Zhifei Biological Products Co. Ltd.

Hualan Biological Engineering Inc.

Incepta Pharmaceuticals Ltd.

Walvax Biotechnology Co. Ltd

Market Segmentation

The Global Meningococcal Vaccine Market Share, Demand provides the most up-to-date Pharmaceuticals industry data on the actual market situation, size, trends and future outlook. The research includes historic data from 2021 to 2023 and forecasts until 2032.

By Vaccine Serotype

MenACWY

MenB and MenBC

MenC

MenA

MenAC

By Vaccine Type

Conjugate

Polysaccharide

Subcapsular

By End-User

Pediatric

Adult

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Travelers

Regions Coverd

North America

U.S.

Canada

Europe

U.K.

Germany

France

Spain

Italy

Russia

Nordic

Benelux

Rest of Europe

APAC

China

Korea

Japan

India

Australia

Singapore

Taiwan

South East Asia

Rest of Asia-Pacific

Middle East and Africa

UAE

Turkey

Saudi Arabia

South Africa

Egypt

Nigeria

Rest of MEA

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

LATAM

Brazil

Mexico

Argentina

Chile

Colombia

Rest of LATAM

Reasons for Doing the Study:

This report is an update of an earlier (2023) Research study. Since the previous edition of this report was published, the Public Safety and Security market has continued to evolve. In particular, the overall market growth rates forecast in the previous edition now appear to have been too high, extending the time-line for the market's development. In order to give its readers, the most up-to-date and accurate assessment of future market opportunities.

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents:

- 1 Executive Summary
- 2 Research Scope & Segmentation
 - 2.1 Research Objectives
 - 2.2 Limitations & Assumptions
 - 2.3 Market Scope & Segmentation
 - 2.4 Currency & Pricing Considered
- 3 Market Opportunity Assessment
 - 3.1 Emerging Regions / Countries
 - 3.2 Emerging Companies
 - 3.3 Emerging Applications / End Use
- 4 Market Trends
 - 4.1 Drivers
 - 4.2 Market Warning Factors
 - 4.3 Latest Macro Economic Indicators
 - 4.4 Geopolitical Impact
 - 4.5 Technology Factors
- 5 Market Assessment
 - 5.1 Porters Five Forces Analysis
 - 5.2 Value Chain Analysis
- 6 Global Meningococcal Vaccine Market Size Analysis
 - 6.1 By Vaccine Serotype
 - 6.1.1 MenACWY
 - 6.1.2 MenB and MenBC
 - 6.1.3 MenC
 - 6.1.4 MenA
 - 6.1.5 MenAC

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2 By Vaccine Type
 - 6.2.1 Conjugate
 - 6.2.2 Polysaccharide
 - 6.2.3 Subcapsular
- 6.3 By End-User
 - 6.3.1 Pediatric
 - 6.3.2 Adult
 - 6.3.3 Travelers
- 7 North America Market Analysis
 - 7.1 By Vaccine Serotype
 - 7.1.1 MenACWY
 - 7.1.2 MenB and MenBC
 - 7.1.3 MenC
 - 7.1.4 MenA
 - 7.1.5 MenAC
 - 7.2 By Vaccine Type
 - 7.2.1 Conjugate
 - 7.2.2 Polysaccharide
 - 7.2.3 Subcapsular
 - 7.3 By End-User
 - 7.3.1 Pediatric
 - 7.3.2 Adult
 - 7.3.3 Travelers
 - 7.3 U.S.
 - 7.4 Canada
- 8 Europe Market Analysis
 - 8.1 By Vaccine Serotype
 - 8.1.1 MenACWY
 - 8.1.2 MenB and MenBC
 - 8.1.3 MenC
 - 8.1.4 MenA
 - 8.1.5 MenAC
 - 8.2 By Vaccine Type
 - 8.2.1 Conjugate
 - 8.2.2 Polysaccharide
 - 8.2.3 Subcapsular
 - 8.3 By End-User
 - 8.3.1 Pediatric
 - 8.3.2 Adult
 - 8.3.3 Travelers
 - 8.3 U.K.
 - 8.4 Germany
 - 8.5 France
 - 8.6 Spain
 - 8.7 Italy
 - 8.8 Russia
 - 8.9 Nordic

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.10 Benelux
- 8.11 Rest of Europe
- 9 APAC Market Analysis
 - 9.1 By Vaccine Serotype
 - 9.1.1 MenACWY
 - 9.1.2 MenB and MenBC
 - 9.1.3 MenC
 - 9.1.4 MenA
 - 9.1.5 MenAC
 - 9.2 By Vaccine Type
 - 9.2.1 Conjugate
 - 9.2.2 Polysaccharide
 - 9.2.3 Subcapsular
 - 9.3 By End-User
 - 9.3.1 Pediatric
 - 9.3.2 Adult
 - 9.3.3 Travelers
 - 9.3 China
 - 9.4 Korea
 - 9.5 Japan
 - 9.6 India
 - 9.7 Australia
 - 9.8 Taiwan
 - 9.9 South East Asia
 - 9.10 Rest of Asia-Pacific
- 10 Middle East and Africa Market Analysis
 - 10.1 By Vaccine Serotype
 - 10.1.1 MenACWY
 - 10.1.2 MenB and MenBC
 - 10.1.3 MenC
 - 10.1.4 MenA
 - 10.1.5 MenAC
 - 10.2 By Vaccine Type
 - 10.2.1 Conjugate
 - 10.2.2 Polysaccharide
 - 10.2.3 Subcapsular
 - 10.3 By End-User
 - 10.3.1 Pediatric
 - 10.3.2 Adult
 - 10.3.3 Travelers
 - 10.3 UAE
 - 10.4 Turkey
 - 10.5 Saudi Arabia
 - 10.6 South Africa
 - 10.7 Egypt
 - 10.8 Nigeria
 - 10.9 Rest of MEA

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11 LATAM Market Analysis
 - 11.1 By Vaccine Serotype
 - 11.1.1 MenACWY
 - 11.1.2 MenB and MenBC
 - 11.1.3 MenC
 - 11.1.4 MenA
 - 11.1.5 MenAC
 - 11.2 By Vaccine Type
 - 11.2.1 Conjugate
 - 11.2.2 Polysaccharide
 - 11.2.3 Subcapsular
 - 11.3 By End-User
 - 11.3.1 Pediatric
 - 11.3.2 Adult
 - 11.3.3 Travelers
 - 11.3 Brazil
 - 11.4 Mexico
 - 11.5 Argentina
 - 11.6 Chile
 - 11.7 Colombia
 - 11.8 Rest of LATAM
- 12 Competitive Landscape
 - 12.1 Global Meningococcal Vaccine Market Share By Players
 - 12.2 M & A Agreements & Collaboration Analysis
- 13 Market Players Assessment
 - 13.1 American International Industries (GIGI)
 - 13.1.1 Overview
 - 13.1.2 Business Information
 - 13.1.3 Revenue
 - 13.1.4 ASP
 - 13.1.5 Swot Analysis
 - 13.1.6 Recent Developments
 - 13.2 Sanofi S.A.
 - 13.3 Pfizer Inc.
 - 13.4 Serum Institute of India Pvt. Ltd
 - 13.5 Bio-Manguinhos
 - 13.6 Bio-Med Pvt. Limited
 - 13.7 Chongqing Zhifei Biological Products Co. Ltd.
 - 13.8 Hualan Biological Engineering Inc.
 - 13.9 Incepta Pharmaceuticals Ltd.
 - 13.10 Walvax Biotechnology Co. Ltd
- 14 Research Methodology
 - 14.1 Research Data
 - 14.1.1 Secondary Data
 - 14.1.1.1 Major secondary sources
 - 14.1.1.2 Key data from secondary sources
 - 14.1.2 Primary Data

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.1.2.1 Key data from primary sources
- 14.1.2.2 Breakdown of primaries
- 14.1.3 Secondary And Primary Research
 - 14.1.3.1 Key industry insights
- 14.2 Market Size Estimation
 - 14.2.1 Bottom-Up Approach
 - 14.2.2 Top-Down Approach
 - 14.2.3 Market Projection
- 14.3 Research Assumptions
 - 14.3.1 Assumptions
- 14.4 Limitations
- 14.5 Risk Assessment
- 15 Appendix
 - 15.1 Discussion Guide
 - 15.2 Customization Options
 - 15.3 Related Reports
- 16 Disclaimer

Meningococcal Vaccine Market Size, Share & Trends Analysis Report By Vaccine Serotype (MenACWY, MenB and MenBC, MenC, MenA, MenAC), By Vaccine Type (Conjugate, Polysaccharide, Subcapsular), By End-User (Pediatric, Adult, Travelers) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Report | 2023-04-24 | 0 pages | Straits Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4500.00
	Global Site License	\$5500.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-02-23

Signature

A large, empty rectangular box intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com